lurasidone injection suspension (DSP-1349M) / Sumitomo Pharma - LARVOL DELTA

Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. (PubMed, Mol Psychiatry) - "The first included monotherapy studies and studies in which the two drugs used were specified (i.e., aripiprazole, aripiprazole once monthly, aripiprazole+lamotrigine, aripiprazole+valproate, asenapine, carbamazepine, lamotrigine, lamotrigine+valproate, lithium, lithium+oxcarbazepine, lithium+valproate, olanzapine, paliperidone, quetiapine, risperidone long-acting injection, valproate, and placebo). The second included studies on second-generation antipsychotic combination therapies (SGAs) (i.e., aripiprazole, lurasidone, olanzapine, quetiapine, and ziprasidone) with lithium or valproate (LIT/VAL) compared with placebo with LIT/VAL...Lurasidone+LIT/VAL and quetiapine+LIT/VAL outperformed placebo+LIT/VAL for all-cause discontinuation. Treatment efficacy, tolerability, and safety profiles differed among treatments."

Journal • Retrospective data • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

[VIRTUAL] FACIAL DYSTONIA MASQUERADING AS ANGIOEDEMA (ACAAI 2020) - "He was managed with intramuscular epinephrine, steroids, and antihistamines on 10 occasions with rapid resolution of symptoms. He follows with a psychiatrist for anxiety, managed with lurasidone and hydroxyzine for the past year...His lurasidone was discontinued and he was started on bromocriptine 1 mg twice a day for three days. He had resolution of symptoms with no further episodes, and was discharged with follow up with his psychiatrist.Discussion We present a case of facial dystonia likely secondary to atypical antipsychotic use where tongue protrusion was initially managed as histaminergic angioedema. This case highlights the importance of identifying true angioedema in contrast to disorders mimicking angioedema."

Allergy • Cardiovascular • CNS Disorders • Dystonia • Immunology • Mood Disorders • Movement Disorders • Psychiatry

Lurasidone inhibits NMDA/glutamate antagonist-induced functional abnormality of thalamocortical glutamatergic transmission via 5-HT receptor blockade. (PubMed, Br J Pharmacol) - "The present results indicate that MK-801-induced insular l-glutamate release is generated by activation of thalamo-insular glutamatergic transmission via MDTN GABAergic disinhibition resulting from NMDA/glutamate receptor inhibition in the MDTN and RTN. Lurasidone inhibited this MK-801-evoked insular l-glutamate release through inhibition of excitatory 5-HT7 receptor in the MDTN. These effects on thalamo-insular glutamatergic transmission may contribute to the antipsychotic and mood-stabilizing actions of lurasidone."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. (PubMed, Am J Psychiatry) - "The 95% effective doses and the doses equivalent to 1 mg of oral risperidone, respectively, were as follows: amisulpride for patients with positive symptoms, 537 mg/day and 85.8 mg; aripiprazole, 11.5 mg/day and 1.8 mg; aripiprazole LAI (lauroxil), 463 mg every 4 weeks and 264 mg; asenapine, 15.0 mg/day and 2.4 mg; brexpiprazole, 3.36 mg/day and 0.54 mg; haloperidol, 6.3 mg/day and 1.01 mg; iloperidone, 20.13 mg/day and 3.2 mg; lurasidone, 147 mg/day and 23.5 mg; olanzapine, 15.2 mg/day and 2.4 mg; olanzapine LAI, 277 mg every 2 weeks and 3.2 mg; paliperidone, 13.4 mg/day and 2.1 mg; paliperidone LAI, 120 mg every 4 weeks and 1.53 mg; quetiapine, 482 mg/day and 77 mg; risperidone, 6.3 mg/day and 1 mg; risperidone LAI, 36.6 mg every 2 weeks and 0.42 mg; sertindole, 22.5 mg/day and 3.6 mg; and ziprasidone, 186 mg/day and 30 mg...In chronic schizophrenia patients with acute exacerbations, doses higher than the identified 95% effective doses may on average not provide more..."

Journal • Retrospective data • CNS Disorders • Schizophrenia

Antipsychotic lurasidone: Behavioural and pharmacokinetic data in C57BL/6 mice. (PubMed, Pharmacol Biochem Behav) - "This last result gives important data to adapt oral chronic administration of lurasidone with a more ethical perspective in comparison with chronic i.p. injections. This study brings tools to improve pharmacological validity of preclinical models of psychiatric diseases, and to adapt dosage of antipsychotics according to the route used."

Journal • PK/PD data • Preclinical • Alzheimer's Disease • CNS Disorders • Psychiatry • Schizophrenia

Roux-en-Y Gastric Bypass and Antipsychotic Therapeutic Drug Monitoring: Two Cases. (PubMed, J Pharm Pract) - "Her medications prior and following the procedure include bupropion, fluvoxamine, lurasidone, methylphenidate, oxcarbazepine, and verapamil...Medications on admission included phenytoin, oxcarbazepine, risperidone, and venlafaxine...We describe the contributions of drug-drug interactions, medication release mechanisms, and food coadministration that may have affected our therapeutic drug monitoring. Our therapeutic drug monitoring results need to be replicated prior to use in the general population but suggest that oral extended-release drug formulations are particularly poor choices and that nonoral antipsychotic formulations may be preferred in some patients who have undergone RYBG."

Clinical • Journal

Psychotropic-Induced Priapism in a Treatment-Refractory Patient: A Case Report. (PubMed, J Pharm Pract) - "All incidences were potentially attributable to psychotropic medications, with chlorpromazine, risperidone, trazodone, and quetiapine being the most likely culprits...While on clozapine, fluphenazine, haloperidol, lurasidone, and olanzapine at varying times, the patient did not appear to develop priapism...This is not the first case to describe this effect, but will give clinicians a timeline of events and medications that did and did not appear to elicit priapism in a patient with treatment-refractory schizoaffective disorder. Knowledge of which psychotropic medications may be more likely to induce priapism is crucial to preventing long-term penile damage."

Clinical • Journal

Case Report: Early Onset Psychosis in Adolescent Identical Twins (APA 2019) - "Due to multiple psychiatric hospitalizations, both W and Z have been on similar medication regimens with Valproate, Lurasidone, Hydroxyzine, and Aripiprazole with sub-therapeutic effects. Medications were found to be sub therapeutic, with a hope that over time, long acting injectable antipsychotics would improve adherence and overall symptoms. Reports of twin pairing developing psychosis at the same time are rare, but can show a strong genetic predisposition to psychosis in relatives with a history of mental illness."

Clinical

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia (clinicaltrials.gov) - P1; N=40; Completed; Sponsor: Sunovion; Recruiting ➔ Completed

Clinical • Trial completion

Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats. (PubMed, Clin Psychopharmacol Neurosci) - "Aripiprazole and ziprasidone also show little weight gain and can reduce olanzapine-induced food intake and weight gain in animals, paralleling some clinical findings. : These findings support our hypotheses in that lurasidone, in addition to a lack of effect on acute food intake and short term weight gain, can reduce olanzapine-induced food intake and weight gain in rats. This indicates the drug to have an active anti-hyperphagic mechanism, rather than solely the absence of a drug-induced weight gain that is such a severe limitation of drugs such as olanzapine."

Journal • Preclinical

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Sunovion; Trial completion date: Oct 2019 ➔ Mar 2019; Trial primary completion date: Oct 2019 ➔ Mar 2019

Clinical • Trial completion date • Trial primary completion date